Go back

Industry studies blame regulation for variable access to medicines

Image: PhotoAlto/Sigrid Olsson, via Getty Images

Pharmaceutical leader says delays “cannot be solved” by EU innovation reforms

A new set of studies carried out by the pharmaceutical industry blame regulation for the variable access to medicines that exists across the EU, and which politicians are attempting to reduce through reforms the industry opposes.

Three reports, published on 13 June by the European Federation of Pharmaceutical Industries and Associations, concur with the political consensus that there continue to be big differences in the times it takes for patients to gain access to new medicines in different European countries.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.